- Home
- JLS vs ONCY Comparison
JLS vs ONCY Comparison
Compare JLS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- ONCY
- Stock Information
- Founded
- JLS 2009
- ONCY 1998
- Country
- JLS United States
- ONCY Canada
- Employees
- JLS N/A
- ONCY N/A
- Industry
- JLS Investment Managers
- ONCY Pharmaceuticals and Biotechnology
- Sector
- JLS Finance
- ONCY Health Care
- Exchange
- JLS Nasdaq
- ONCY Nasdaq
- Market Cap
- JLS 103.4M
- ONCY 89.7M
- IPO Year
- JLS N/A
- ONCY 1999
- Fundamental
- Price
- JLS $18.76
- ONCY $1.00
- Analyst Decision
- JLS
- ONCY Strong Buy
- Analyst Count
- JLS 0
- ONCY 6
- Target Price
- JLS N/A
- ONCY $6.00
- AVG Volume (30 Days)
- JLS 26.6K
- ONCY 887.9K
- Earning Date
- JLS 01-01-0001
- ONCY 11-12-2025
- Dividend Yield
- JLS 9.33%
- ONCY N/A
- EPS Growth
- JLS N/A
- ONCY N/A
- EPS
- JLS N/A
- ONCY N/A
- Revenue
- JLS N/A
- ONCY N/A
- Revenue This Year
- JLS N/A
- ONCY N/A
- Revenue Next Year
- JLS N/A
- ONCY N/A
- P/E Ratio
- JLS N/A
- ONCY N/A
- Revenue Growth
- JLS N/A
- ONCY N/A
- 52 Week Low
- JLS $15.48
- ONCY $0.33
- 52 Week High
- JLS $17.97
- ONCY $1.51
- Technical
- Relative Strength Index (RSI)
- JLS 46.73
- ONCY 40.44
- Support Level
- JLS $18.48
- ONCY $1.03
- Resistance Level
- JLS $18.78
- ONCY $1.15
- Average True Range (ATR)
- JLS 0.20
- ONCY 0.07
- MACD
- JLS -0.00
- ONCY -0.00
- Stochastic Oscillator
- JLS 57.44
- ONCY 36.96
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.